Login
Companies $CDNA
$73.69 -$0.03 (0.04%) After hours
CareDx, Inc. logo

CareDx, Inc.

caredx.com

What Do They Do?

Provides molecular tests and laboratory and digital care solutions for transplant patients, clinicians and transplant centers.

How Do They Make Money?

Testing services make up 72% of revenue; third-party payers are billed when results are delivered to providers. Laboratory products are sold to end users, distributors and strategic partners when shipped or delivered, while patient and digital solutions earn revenue from software subscriptions and licenses plus medication sales.

revenue
SegmentShareRevenue
Testing services revenue
Sold outright

72%
FY2022: 82%
Product revenue
Sold outright

13%
FY2022: 9.1%
Patient and digital solutions revenue
Mix

15%
FY2022: 9.0%

Who Are Their Customers?

Healthcare providers order tests for transplant patients, while third-party payers are generally billed; transplant centers are the software customers. CareDx's U.S. regional teams sell into specific transplant centers, while distributors serve centers outside Western Europe; products also go to end users, distributors and strategic partners.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2023: 40% from one customer

Do Revenues Turn Into Profits?

No. It lost $21.4M in FY2025.

Operating income, FY2025
−8% of revenue
▼ Turned to a loss vs FY2024 ($40.8M, 12%)
Net income, FY2025
−6% of revenue
▼ Turned to a loss vs FY2024 ($52.5M, 16%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +39%
vs $100.1M in Q3 FY2025
Net income
▲ +1052%
vs $1.7M in Q3 FY2025
Testing services revenue share of revenue vs 72.1% in Q3 FY2025
  • Jul 30, 2026 Raised revenue and adjusted EBITDA guidance It lifted both full-year ranges from the levels announced earlier in the year.
  • Jul 7, 2026 Sold Lab Products and completed the Naveris acquisition CareDx sold the Lab Products business to Eurobio and completed its acquisition of Naveris.

Growing. Revenue grew 28% in 4 years, from $296.4M in FY2021 to $379.8M in FY2025, about 6% a year.

Revenue over time
Testing services revenue Product revenue Patient and digital solutions revenue
$500M$250M$0

Who Do They Compete With?

Competes with Natera, Eurofins Transplant Genomics, Devyser Diagnostics, Insight Molecular Diagnostics, Thermo Fisher, Omixon, GenDx, BAG, Qiagen, Immucor, and Epic

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support